1. Home
  2. VCTR vs RARE Comparison

VCTR vs RARE Comparison

Compare VCTR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCTR
  • RARE
  • Stock Information
  • Founded
  • VCTR 2013
  • RARE 2010
  • Country
  • VCTR United States
  • RARE United States
  • Employees
  • VCTR N/A
  • RARE N/A
  • Industry
  • VCTR Investment Managers
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCTR Finance
  • RARE Health Care
  • Exchange
  • VCTR Nasdaq
  • RARE Nasdaq
  • Market Cap
  • VCTR 4.0B
  • RARE 3.6B
  • IPO Year
  • VCTR 2018
  • RARE 2014
  • Fundamental
  • Price
  • VCTR $57.44
  • RARE $37.82
  • Analyst Decision
  • VCTR Buy
  • RARE Strong Buy
  • Analyst Count
  • VCTR 9
  • RARE 15
  • Target Price
  • VCTR $68.33
  • RARE $95.93
  • AVG Volume (30 Days)
  • VCTR 330.6K
  • RARE 736.1K
  • Earning Date
  • VCTR 05-08-2025
  • RARE 05-01-2025
  • Dividend Yield
  • VCTR 2.94%
  • RARE N/A
  • EPS Growth
  • VCTR 40.38
  • RARE N/A
  • EPS
  • VCTR 4.38
  • RARE N/A
  • Revenue
  • VCTR $893,477,000.00
  • RARE $560,230,000.00
  • Revenue This Year
  • VCTR $39.57
  • RARE $19.15
  • Revenue Next Year
  • VCTR $11.95
  • RARE $32.11
  • P/E Ratio
  • VCTR $13.11
  • RARE N/A
  • Revenue Growth
  • VCTR 8.82
  • RARE 29.01
  • 52 Week Low
  • VCTR $41.30
  • RARE $36.71
  • 52 Week High
  • VCTR $73.42
  • RARE $60.37
  • Technical
  • Relative Strength Index (RSI)
  • VCTR 39.47
  • RARE 39.28
  • Support Level
  • VCTR $59.06
  • RARE $36.71
  • Resistance Level
  • VCTR $63.25
  • RARE $39.21
  • Average True Range (ATR)
  • VCTR 1.80
  • RARE 1.32
  • MACD
  • VCTR 0.25
  • RARE 0.01
  • Stochastic Oscillator
  • VCTR 30.67
  • RARE 29.02

About VCTR Victory Capital Holdings Inc.

Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: